Bristol-Myers Squibb Company (BMY)
| Market Cap | 114.87B +16.6% |
| Revenue (ttm) | 48.48B +1.8% |
| Net Income | 7.28B +34.3% |
| EPS | 3.57 +33.7% |
| Shares Out | 2.04B |
| PE Ratio | 15.75 |
| Forward PE | 9.18 |
| Dividend | $2.52 (4.48%) |
| Ex-Dividend Date | Apr 2, 2026 |
| Volume | 10,419,712 |
| Open | 56.44 |
| Previous Close | 56.59 |
| Day's Range | 55.57 - 56.90 |
| 52-Week Range | 42.52 - 62.89 |
| Beta | 0.26 |
| Analysts | Buy |
| Price Target | 61.73 (+9.74%) |
| Earnings Date | Apr 30, 2026 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for BMY stock is "Buy." The 12-month stock price target is $61.73, which is an increase of 9.74% from the latest price.
News
Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026.
Bristol-Myers Squibb Company Transcript: AGM 2026
The meeting highlighted strong growth in the portfolio, robust financial performance, and continued dividends. All management proposals passed with high approval, while a shareholder proposal for an independent board chair was rejected. Key risks include upcoming patent expirations and stock underperformance.
Bristol Myers Squibb Launches “Won't Lose” Media Campaign Ahead of FIFA World Cup 2026™
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Launches "Won't Lose" Media Campaign Ahead of FIFA World Cup 2026™.
Big Pharma M&A set for mega year as patent expiries drive deal urgency
Biotech dealmaking is on pace for a bumper year in 2026, with large drugmakers on an acquisition spree to boost their pipelines ahead of upcoming patent losses.
Bristol Myers price target raised to $66 from $64 at Citi
Citi raised the firm’s price target on Bristol Myers (BMY) to $66 from $64 and keeps a Neutral rating on the shares. The firm updated the company’s model post the
Bristol-Myers Squibb Company Earnings Call Transcript: Q1 2026
Q1 2026 saw 1% revenue growth to $11.5B, with a 9% rise in the growth portfolio and strong launches for key assets. Pipeline advanced with regulatory milestones and positive pivotal data, while guidance was reaffirmed and performance is tracking toward the upper end of ranges.
Bristol Myers Squibb Logs Higher Sales, Profit
Bristol Myers Squibb posted higher first-quarter revenue boosted by its portfolio of newer treatments for heart and blood conditions.
Options Volatility and Implied Earnings Moves Today, April 30, 2026
Today, several major companies are expected to report earnings: Altria Group (MO), Apple (AAPL), Bristol-Myers Squibb (BMY), Caterpillar (CAT), Eli Lilly & Co (LLY), Mastercard (MA), Merck & Company (...
Bristol Myers posts higher-than-expected quarterly profit on blood thinner, cancer sales
Bristol Myers Squibb reported a first-quarter profit that beat Wall Street expectations on Thursday, helped by better-than-expected growth of blood thinner Eliquis as well as newer cancer medicines.
Bristol Myers Squibb Reports First Quarter Financial Results for 2026
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports First Quarter Financial Results for 2026.
Notable companies reporting before tomorrow’s open
Notable companies reporting before tomorrow’s open, with earnings consensus, include Eli Lilly (LLY), consensus $6.97… MasterCard (MA), consensus $4.41… Caterpillar (CAT), consensus $4.65… Merck (MRK)...
Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban's online pharmacy
Bristol-Myers Squibb and Pfizer said on Friday they will start selling their jointly developed blood thinner through billionaire entrepreneur Mark Cuban's online pharmacy beginning April 27.
Bristol Myers-Pfizer Alliance launch collaboration with Mark Cuban for Eliquis
The Bristol Myers Squibb-Pfizer (BMY) – Pfizer (PFE) Alliance announced the launch of a collaboration with Mark Cuban Cost Plus Drug Company to offer Eliquis, or apixaban, on CostPlusDrugs.com. Eliqui...
Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Eliquis--Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company.
Atrium Therapeutics earns $15M development milestone payment from Bristol Myers
Atrium Therapeutics (RNA) has earned a $15M development milestone payment from Bristol Myers (BMY). The milestone was achieved upon the successful delivery of a development candidate for the first lic...
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced...
Foundation Medicine expands collaboration with Bristol Myers
Foundation Medicine announced an expansion to its collaboration with Bristol Myers (BMY) Squibb to develop FoundationOneCDx as a next-generation sequencing-based companion diagnostic to identify patie...
Foundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous MTAP Deletion
BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a global precision medicine company, today announced an expansion to its collaboration with Bristol Myers Squibb (NYSE: BMY) to develop FoundationOn...
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet signific...
Bristol Myers Squibb call volume above normal and directionally bullish
Bullish option flow detected in Bristol Myers (BMY) Squibb with 13,618 calls trading, 1.2x expected, and implied vol increasing over 1 point to 31.90%. Jun-26 62.5 calls and Jun-26 65
Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases
– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –
Bristol Myers price target lowered to $67 from $68 at BofA
BofA analyst Jason Gerberry lowered the firm’s price target on Bristol Myers (BMY) to $67 from $68 and keeps a Buy rating on the shares. The firm adjusted several targets
Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours
Oxford, UK and San Jose, California , 9 April 2026 – Oxford BioTherapeutics (“OBT”), is a clinical stage oncology company focused on the discovery and development of immuno-oncology (IO) and Antibody ...
Bristol Myers price target raised to $54 from $45 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Bristol Myers (BMY) to $54 from $45 and keeps a Neutral rating on the shares. The firm does not expect the Q1
15 stocks to put on your list to buy when the market recovers
The stock market's weakness might not be over — but it's not too early to start building a list of stocks to consider buying when investors are willing to take on more risk.